UBS Group Issues Positive Forecast for Kenvue (NYSE:KVUE) Stock Price

Kenvue (NYSE:KVUE) had its target price lifted by equities research analysts at UBS Group from $19.00 to $20.00 in a note issued to investors on Monday, Benzinga reports. The brokerage presently has a “neutral” rating on the stock. UBS Group‘s price objective suggests a potential upside of 3.04% from the stock’s previous close.

Several other equities research analysts also recently weighed in on the stock. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kenvue in a report on Friday, September 11th. Barclays raised their target price on shares of Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research note on Tuesday, July 21st. Zacks Research downgraded shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Wall Street Zen lowered shares of Kenvue from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, HSBC decreased their price objective on shares of Kenvue from $20.00 to $19.00 and set a “hold” rating for the company in a report on Monday, August 10th. Thirteen research analysts have rated the stock with a Hold rating. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $19.44.

Kenvue Stock Performance

Kenvue stock traded up $0.10 during mid-day trading on Monday, hitting $19.41. 66,595,389 shares of the company’s stock traded hands, compared to its average volume of 20,937,440. The company has a quick ratio of 0.71, a current ratio of 1.01 and a debt-to-equity ratio of 0.67. Kenvue has a one year low of $14.06 and a one year high of $20.13. The firm has a 50 day moving average price of $18.40 and a 200 day moving average price of $18.19. The company has a market cap of $37.28 billion, a PE ratio of 22.06, a price-to-earnings-growth ratio of 1.78 and a beta of 0.48.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Friday, October 30th. The company reported $0.29 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.29. The company had revenue of $3.89 billion during the quarter, compared to analysts’ expectations of $3.86 billion. Kenvue had a return on equity of 21.52% and a net margin of 10.88%. The company’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.28 earnings per share. On average, equities analysts forecast that Kenvue will post 1.14 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of KVUE. CoreCap Advisors LLC grew its holdings in Kenvue by 64.9% during the second quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock worth $29,000 after acquiring an additional 591 shares during the period. Triumph Capital Management lifted its holdings in Kenvue by 24.2% in the 3rd quarter. Triumph Capital Management now owns 3,060 shares of the company’s stock valued at $54,000 after acquiring an additional 596 shares during the last quarter. Montag A & Associates Inc. boosted its position in shares of Kenvue by 6.3% during the 1st quarter. Montag A & Associates Inc. now owns 10,156 shares of the company’s stock valued at $175,000 after purchasing an additional 600 shares in the last quarter. Strive Financial Group LLC boosted its position in shares of Kenvue by 5.2% during the 2nd quarter. Strive Financial Group LLC now owns 12,263 shares of the company’s stock valued at $234,000 after purchasing an additional 609 shares in the last quarter. Finally, Mondrian Investment Partners LTD boosted its position in shares of Kenvue by 0.8% during the 3rd quarter. Mondrian Investment Partners LTD now owns 75,868 shares of the company’s stock valued at $1,340,000 after purchasing an additional 621 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Kenvue Company Profile

Kenvue Inc is a consumer health company that develops, markets and sells products designed to support everyday health and personal care. Its portfolio spans over-the-counter medicines, skin health and beauty, and essential health products, serving consumers through retail, e-commerce and other distribution channels.

The company’s brands include Tylenol, Motrin, Zyrtec and Benadryl in self-care; Neutrogena, Aveeno and Clean & Clear in skin health and beauty; and Listerine, Johnson’s and OGX in oral care, baby care and hair care.